Establishing a Short-term Response Endpoint for mCRPC Trials
After looking at 8 short-term endpoints based on PSA and CTCs, absence of tumor cells at week 13 was considered the best predictor of overall survival.
All articles by Alexander M. Castellino, PhD
Dual HER2 Blockade Superior in HER2+ HR+ Breast Cancer
When combined with an aromatase inhibitor, dual HER2 blockade shows superior PFS compared with lapatinib or trastuzumab alone in some women with breast cancer.
Electronic Patient-reported Outcome System Improves Survival Among Patients With Cancer
A study showed that symptom monitoring by integrating electronic patient-reported outcomes into clinical practice vs usual care extended OS by more than 5 months.
PALOMA-1 Update: Survival With Palbociclib Not Significantly Improved in ER+/HER2- Breast Cancer
Data from PALOMA-1/TRIO-18 showed that combining palbociclib and letrozole did not significantly improve survival compared with letrozole alone among patients with breast cancer.
Abemaciclib Plus Fulvestrant Is Effective Therapy in Endocrine-resistant Breast Cancer
Patients with breast cancer who progress on endocrine therapy and are then treated with abemaciclib and fulvestrant have a 45% decreased risk for progression.
Aldoxorubicin Improves Outcomes in Relapsed/Refractory Sarcoma
Aldoxorubicin significantly prolongs PFS and provides better objective response rates than investigators’ choice of treatment or standard of care in the treatment of soft tissue sarcoma.
Korean Red Ginseng Improves Cancer-related Fatigue in Colorectal Cancer
Consuming Korean red ginseng was reported to improve cancer-related fatigue among Korean patients with colorectal cancer (CRC) treated with FOLFOX.
Promising Activity Reported for Nivolumab in Gynecologic Cancers
Nivolumab, a programmed death (PD)-1 inhibitor, showed promising clinical activity in recurrent or metastatic cervical cancers and provides a promising new approach to treatment.
Sarcoma: Next-generation Sequencing Has Implications for Diagnosis and Treatment
A retrospective analysis of next-generation sequencing profiles has diagnostic and therapeutic implications for patients with soft-tissue or bone sarcoma.
Personalizing Care for Patients With Sarcoma
The landscape of complex genetic mutations in sarcomas seen through next-generation sequence profiling provides a rationale for a study to match patients to the appropriate therapy.
- Loading...
Loading...
Next post in ASCO 2017
Loading... 
Loading...